Skip to main content

Table 3 Drug resistance conferring mutations from the current study

From: Seroprevalence and genotypic characterization of HBV among low risk voluntary blood donors in Nairobi, Kenya

Accession number

Mutations

Drug resisted

HBsAg sero status

MT185643

Y126H

Adefovir dipivoxil(ADV)

Negative

M129L

Lamivudine

V163I

Lamivudine

MT185642

Y126H

Adefovir dipivoxil(ADV)

Negative

M129L

Lamivudine

V163I

Lamivudine

MT185644

Y126H

Adefovir dipivoxil(ADV)

Positive

M129L

Lamivudine

V163I

Lamivudine

MT185645

Y126H

Adefovir dipivoxil(ADV)

Negative

M129L

Lamivudine

V163I

Lamivudine

S202G

Entecavir & Lamivudine

MT185646

Y126H

Adefovir dipivoxil(ADV)

Negative

M129L

Lamivudine

V163I

Lamivudine

MT185647

Y126H

Adefovir dipivoxil(ADV)

Negative

M129L

Lamivudine

V163I

Lamivudine

MT185648

M129L

Lamivudine

Negative

V163I

Lamivudine

MT185649

M129L

Lamivudine

Positive

V163I

Lamivudine

MT185650

M129L

Lamivudine

Negative

V163I,

Lamivudine

A181T

Lamivudine (zeffix), Adefovir(Hepsera), Telbivudine(Tyzeka and Sebivo)

  1. These mutations were identified using two online tools Geno2Pheno HBV database (HBVdb) (https://hbv.geno2pheno.org/) and HBVseq program from HIV Stanford database (https://hivdb.stanford.edu/HBV/HBVseq/development/HBVseq.html). The mutations are listed for each of the sample where they occurred